Datametrex - CEO, Marshall Gunter.
CEO, Marshall Gunter.
Source: LinkedIn
  • Datametrex AI (DM) subsidiary, Medi-Call, has created a new subscription plan
  • Patients can pick which type of healthcare service they need and not pay for additional treatments that do not suit their healthcare needs
  • This new membership plan brings affordability and accessibility to younger students who may only need basic telehealth services
  • Medi-call is a subscription-based software-as-a-service (SaaS) mobile application that connects patients with doctors
  • Datametrex AI utilizes artificial intelligence (AI) to create solutions for the cyber security, telehealth, and electric vehicle (EV) verticals
  • Datametrex AI Limited (DM) is trading at C$0.08 per share at 11 am ET

Datametrex AI (DM) subsidiary, Medi-Call Inc., has created a new subscription plan designed to meet the needs of more Canadians.

Creating more membership plans means patients can pick which type of healthcare service they need and not pay for additional treatments that do not suit their healthcare needs.

This new membership plan brings affordability and accessibility to younger students who may only need basic telehealth services such as physician virtual visits, doctor notes and prescriptions.

Marshall Gunter, CEO of Datametrex, commented on the news.

“Our mission is to provide easy access to healthcare to everyone. No long wait times for a physician, just healthcare on our watch. Our modular, affordable membership plans cater to different needs and lifestyles, allowing patients to get more out of their telehealth experience.”

Medi-call is a subscription-based software-as-a-service (SaaS) mobile application that connects patients with doctors.

Datametrex AI Limited is a technology-focused company using artificial intelligence (AI) to create solutions for the cyber security, telehealth, and electric vehicle (EV) verticals.

Datametrex AI Limited (DM) is trading at C$0.08 per share at 11 am ET.


More From The Market Online

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.